Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Alexander van Akkooi MD, PhD, FRACS

Alexander C. J. van Akkooi MD, PhD, FRACS

Chair of Melanoma Surgical Oncology, Melanoma Institute Australia; Associate Professor of Melanoma Surgical Oncology, The University of Sydney, Sydney, Australia

Prof. Dr. Alexander van Akkooi is a board-certified surgical oncologist specializing in cutaneous oncology (melanoma and non-melanoma skin cancer, particularly Merkel cell carcinoma) at the Melanoma Institute Australia, University of Sydney, and Royal Prince Alfred Hospital. He is the immediate past-chairman of the EORTC (European Organization for Research and Treatment of Cancer) Melanoma Group. Prof. Dr. van Akkooi has published over 225 peer-reviewed papers in high-impact journals, including NEJM, The Lancet, The Lancet Oncology, Cell, and Nature Medicine, among others, and has presented at numerous international meetings. He is a member of the European Society for Medical Oncology (ESMO), Society for Melanoma Research (SMR), and American Society of Clinical Oncology (ASCO).

Prof. Dr. van Akkooi was awarded his medical degree from Erasmus University in Rotterdam, the Netherlands. He was a resident in general surgery at Maasstad Ziekenhuis in Rotterdam and underwent residency training in surgical oncology at the Netherlands Cancer Institute in Amsterdam and Erasmus MC Cancer Institute in Rotterdam. His PhD was awarded cum laude in 2011 from Erasmus University on the topic of "Sentinel Node Tumor Load Assessment in Melanoma: Dilemmas and Clinical Management."

Disclosures

  • Advisory board/consultant: Amgen; Bristol-Myers Squibb; MSD-Merck; Merck-Pfizer; NeraCare; Novartis; Pierre Fabre; Provectus; Sanofi; Sirius Medical; 4SC
  • Research funding: (to his institute): Amgen; Merck-Pfizer

Recent Contributions to PracticeUpdate:

  1. Impact of COVID-19 Lockdown on Skin Tumor Burden
  2. Sentinel Node Surveillance in the Absence of Completion Lymph Node Dissection
  3. Neoadjuvant Therapy With Immunotherapy for Stage IIIB-D Melanoma
  4. Pembrolizumab as Adjuvant Treatment for High Risk Melanoma
  5. ESMO 2021: Recommendations From Dr. Alex van Akkooi for Melanoma
  6. Current Options for Managing In-Transit Metastases in Melanoma
  7. Pembrolizumab Plus Ipilimumab After Anti–PD-1/L1 Failure for Melanoma
  8. Sentinel Lymph Node Biopsy in Non-Ulcerated T1b Melanoma
  9. Crossover or Rechallenge With Pembrolizumab in Patients With Resected Melanoma
  10. Neoadjuvant and Adjuvant Nivolumab Plus Relatlimab for Resectable Stage III Melanoma

Elsewhere

Recently Updated